{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T10:32:46Z","timestamp":1752229966353,"version":"3.37.3"},"reference-count":159,"publisher":"Georg Thieme Verlag KG","issue":"06","funder":[{"DOI":"10.13039\/100009157","name":"National Institute on Disability, Independent Living, and Rehabilitation Research","doi-asserted-by":"crossref","award":["90AR5025"],"award-info":[{"award-number":["90AR5025"]}],"id":[{"id":"10.13039\/100009157","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NIDILRR is a center within the Administration for Community Living","award":["ACL"],"award-info":[{"award-number":["ACL"]}]},{"name":"Department of Health and Human Services","award":["HHS"],"award-info":[{"award-number":["HHS"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Neurol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Status epilepticus is a neurological emergency with an outcome that is highly associated with the initial pharmacotherapy management that must be administered in a timely fashion. Beyond first-line therapy of status epilepticus, treatment is not guided by robust evidence. Optimal pharmacotherapy selection for individual patients is essential in the management of seizures and status epilepticus with careful evaluation of pharmacokinetic and pharmacodynamic factors. With the addition of newer antiseizure agents to the market, understanding their role in the management of status epilepticus is critical. Etiology-guided therapy should be considered in certain patients with drug-induced seizures, alcohol withdrawal, or autoimmune encephalitis. Some patient populations warrant special consideration, such as pediatric, pregnant, elderly, and the critically ill. Seizure prophylaxis is indicated in select patients with acute neurological injury and should be limited to the acute postinjury period.<\/jats:p>","DOI":"10.1055\/s-0040-1718721","type":"journal-article","created":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T23:56:18Z","timestamp":1605138978000},"page":"681-695","source":"Crossref","is-referenced-by-count":2,"title":["Principles of Pharmacotherapy of Seizures and Status Epilepticus"],"prefix":"10.1055","volume":"40","author":[{"given":"Caroline","family":"Der-Nigoghossian","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Neurosciences Intensive Care Unit, New York-Presbyterian Hospital\/Columbia University Irving Medical Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eljim P.","family":"Tesoro","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice (MC 886), College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micheal","family":"Strein","sequence":"additional","affiliation":[{"name":"Pharmacotherapy and Outcomes Science and Neurosurgery, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, Virginia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gretchen M.","family":"Brophy","sequence":"additional","affiliation":[{"name":"Pharmacotherapy and Outcomes Science and Neurosurgery, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, Virginia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2020,11,11]]},"reference":[{"issue":"08","key":"ref1","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1001\/jamaneurol.2019.1268","article-title":"Change in mortality of generalized convulsive status epilepticus in high-income countries over time: a systematic review and meta-analysis","volume":"76","author":"A Neligan","year":"2019","journal-title":"JAMA Neurol"},{"issue":"01","key":"ref2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12028-012-9695-z","article-title":"Guidelines for the evaluation and management of status epilepticus","volume":"17","author":"G M Brophy","year":"2012","journal-title":"Neurocrit Care"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5698\/1535-7597-16.1.48","article-title":"Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society","volume":"16","author":"T Glauser","year":"2016","journal-title":"Epilepsy Curr"},{"issue":"03","key":"ref4","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/ana.25416","article-title":"Factors predicting cessation of status epilepticus in clinical practice: data from a prospective observational registry (SENSE)","volume":"85","author":"C Kellinghaus","year":"2019","journal-title":"Ann Neurol"},{"issue":"08","key":"ref5","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/acem.13811","article-title":"Underdosing of benzodiazepines in patients with status epilepticus enrolled in Established Status Epilepticus Treatment Trial","volume":"26","author":"A G Sathe","year":"2019","journal-title":"Acad Emerg Med"},{"issue":"12","key":"ref6","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1056\/NEJM199809173391202","article-title":"A comparison of four treatments for generalized convulsive status epilepticus","volume":"339","author":"D M Treiman","year":"1998","journal-title":"N Engl J Med"},{"issue":"09","key":"ref7","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa002141","article-title":"A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus","volume":"345","author":"B K Alldredge","year":"2001","journal-title":"N Engl J Med"},{"issue":"07","key":"ref8","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1056\/NEJMoa1107494","article-title":"Intramuscular versus intravenous therapy for prehospital status epilepticus","volume":"366","author":"R Silbergleit","year":"2012","journal-title":"N Engl J Med"},{"issue":"02","key":"ref9","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1046\/j.1528-1157.2002.28501.x","article-title":"Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review","volume":"43","author":"J Claassen","year":"2002","journal-title":"Epilepsia"},{"issue":"01","key":"ref10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s12028-010-9445-z","article-title":"A randomized trial for the treatment of refractory status epilepticus","volume":"14","author":"A O Rossetti","year":"2011","journal-title":"Neurocrit Care"},{"issue":"02","key":"ref11","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/BF03189348","article-title":"Pharmacokinetics of midazolam and its main metabolite 1-hydroxymidazolam in intensive care patients","volume":"23","author":"R Boulieu","year":"1998","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"03","key":"ref12","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1528-1157.1996.tb00021.x","article-title":"Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin","volume":"37","author":"J T Backman","year":"1996","journal-title":"Epilepsia"},{"issue":"04","key":"ref13","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2165\/00002018-200831040-00003","article-title":"Propofol infusion syndrome: an overview of a perplexing disease","volume":"31","author":"V Fodale","year":"2008","journal-title":"Drug Saf"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1186\/s13054-015-1112-5","article-title":"Propofol infusion syndrome: a structured review of experimental studies and 153 published case reports","volume":"19","author":"A Kraj\u010dov\u00e1","year":"2015","journal-title":"Crit Care"},{"issue":"04","key":"ref15","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/clpt.1981.66","article-title":"Mechanism of valproate-phenobarbital interaction in epileptic patients","volume":"29","author":"I M Kapetanovi\u0107","year":"1981","journal-title":"Clin Pharmacol Ther"},{"issue":"01","key":"ref16","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/bdd.2510140108","article-title":"Pharmacokinetic interaction between valproic acid and phenobarbital","volume":"14","author":"M Pokrajac","year":"1993","journal-title":"Biopharm Drug Dispos"},{"issue":"07","key":"ref17","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/jps.2600630717","article-title":"Pharmacokinetics and distribution properties of pentobarbital in humans following oral and intravenous administration","volume":"63","author":"M Ehrnebo","year":"1974","journal-title":"J Pharm Sci"},{"issue":"04","key":"ref18","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/j.1875-9114.1998.tb03898.x","article-title":"Hepatic drug metabolism in critical illness","volume":"18","author":"D S McKindley","year":"1998","journal-title":"Pharmacotherapy"},{"issue":"04","key":"ref19","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/clpt.1985.204","article-title":"Pharmacokinetics of high-dose pentobarbital in severe head trauma","volume":"38","author":"C D Bayliff","year":"1985","journal-title":"Clin Pharmacol Ther"},{"issue":"02","key":"ref20","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00007691-198606000-00003","article-title":"Monitoring of pentobarbital plasma levels in critical care patients suffering from increased intracranial pressure","volume":"8","author":"G Heinemeyer","year":"1986","journal-title":"Ther Drug Monit"},{"issue":"05","key":"ref21","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/106002808702100517","article-title":"Pentobarbital pharmacokinetics in patients with severe head injury","volume":"21","author":"D P Wermeling","year":"1987","journal-title":"Drug Intell Clin Pharm"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1093\/brain\/awr215","article-title":"The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol","volume":"134","author":"S Shorvon","year":"2011","journal-title":"Brain"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.nbd.2012.12.015","article-title":"Rapid surface accumulation of NMDA receptors increases glutamatergic excitation during status epilepticus","volume":"54","author":"D E Naylor","year":"2013","journal-title":"Neurobiol Dis"},{"issue":"03","key":"ref24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0304-3940(99)00238-4","article-title":"N-methyl-D-asparate receptor antagonists abolish the maintenance phase of self-sustaining status epilepticus in rat","volume":"265","author":"A M Mazarati","year":"1999","journal-title":"Neurosci Lett"},{"issue":"24","key":"ref25","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1212\/WNL.0b013e318278b685","article-title":"Efficacy and safety of ketamine in refractory status epilepticus in children","volume":"79","author":"A Rosati","year":"2012","journal-title":"Neurology"},{"issue":"08","key":"ref26","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1111\/epi.12247","article-title":"Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study","volume":"54","author":"N Gaspard","year":"2013","journal-title":"Epilepsia"},{"issue":"02","key":"ref27","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s12028-011-9668-7","article-title":"Early ketamine to treat refractory status epilepticus","volume":"16","author":"A H Kramer","year":"2012","journal-title":"Neurocrit Care"},{"issue":"06","key":"ref28","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/cns.12099","article-title":"Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings)","volume":"19","author":"G Mion","year":"2013","journal-title":"CNS Neurosci Ther"},{"issue":"02","key":"ref29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/ANA.0000000000000027","article-title":"Dual effects of ketamine: neurotoxicity versus neuroprotection in anesthesia for the developing brain","volume":"26","author":"J Yan","year":"2014","journal-title":"J Neurosurg Anesthesiol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1126\/science.1835799","article-title":"NMDA antagonist neurotoxicity: mechanism and prevention","volume":"254","author":"J W Olney","year":"1991","journal-title":"Science"},{"issue":"01","key":"ref31","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s12028-013-9950-y","article-title":"The ketamine effect on ICP in traumatic brain injury","volume":"21","author":"F A Zeiler","year":"2014","journal-title":"Neurocrit Care"},{"issue":"05","key":"ref32","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.annemergmed.2010.11.030","article-title":"Clinical practice guideline for emergency department ketamine dissociative sedation: 2011 update","volume":"57","author":"S M Green","year":"2011","journal-title":"Ann Emerg Med"},{"issue":"01","key":"ref33","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00000542-199507000-00014","article-title":"Effects of halothane on glutamate receptor-mediated excitatory postsynaptic currents. A patch-clamp study in adult mouse hippocampal slices","volume":"83","author":"M Perouansky","year":"1995","journal-title":"Anesthesiology"},{"issue":"21","key":"ref34","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMra021261","article-title":"Mechanisms of actions of inhaled anesthetics","volume":"348","author":"J A Campagna","year":"2003","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0378-4274(98)00185-4","article-title":"The molecular mechanism of action of general anesthetics: structural aspects of interactions with GABA(A) receptors","volume":"100\u2013101","author":"R W Olsen","year":"1998","journal-title":"Toxicol Lett"},{"issue":"03","key":"ref36","first-page":"628","article-title":"Positive modulation of human gamma-aminobutyric acid type A and glycine receptors by the inhalation anesthetic isoflurane","volume":"44","author":"N L Harrison","year":"1993","journal-title":"Mol Pharmacol"},{"issue":"04","key":"ref37","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/00000539-200010000-00041","article-title":"The epileptogenic properties of the volatile anesthetics sevoflurane and isoflurane in patients with epilepsy","volume":"91","author":"T Iijima","year":"2000","journal-title":"Anesth Analg"},{"issue":"08","key":"ref38","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1001\/archneur.61.8.1254","article-title":"Treatment of refractory status epilepticus with inhalational anesthetic agents isoflurane and desflurane","volume":"61","author":"S M Mirsattari","year":"2004","journal-title":"Arch Neurol"},{"issue":"02","key":"ref39","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s12028-012-9790-1","article-title":"Treatment of status epilepticus: an international survey of experts","volume":"18","author":"J J Riviello Jr","year":"2013","journal-title":"Neurocrit Care"},{"issue":"01","key":"ref40","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1474-4422(15)00296-3","article-title":"Prehospital treatment with levetiracetam plus clonazepam or placebo plus clonazepam in status epilepticus (SAMUKeppra): a randomised, double-blind, phase 3 trial","volume":"15","author":"V Navarro","year":"2016","journal-title":"Lancet Neurol"},{"issue":"22","key":"ref41","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1905795","article-title":"Randomized trial of three anticonvulsant medications for status epilepticus","volume":"381","author":"J Kapur","year":"2019","journal-title":"N Engl J Med"},{"issue":"06","key":"ref42","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/ana.25249","article-title":"Randomized trial of lacosamide versus fosphenytoin for nonconvulsive seizures","volume":"83","author":"A M Husain","year":"2018","journal-title":"Ann Neurol"},{"issue":"06","key":"ref43","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/epi.13716","article-title":"Lacosamide in status epilepticus: Systematic review of current evidence","volume":"58","author":"A Strzelczyk","year":"2017","journal-title":"Epilepsia"},{"issue":"03","key":"ref44","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s12028-013-9882-6","article-title":"Intravenous lacosamide in refractory seizure clusters and status epilepticus: comparison of 200 and 400\u2009mg loading doses","volume":"20","author":"B Legros","year":"2014","journal-title":"Neurocrit Care"},{"issue":"S 02","key":"ref45","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/epi.14486","article-title":"Intravenous brivaracetam in status epilepticus: a retrospective single-center study","volume":"59","author":"G Kalss","year":"2018","journal-title":"Epilepsia"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.yebeh.2017.03.028","article-title":"Treatment of refractory and super-refractory status epilepticus with brivaracetam: a cohort study from two German university hospitals","volume":"70","author":"A Strzelczyk","year":"2017","journal-title":"Epilepsy Behav"},{"issue":"03","key":"ref47","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/epi4.12230","article-title":"Systematic review of clobazam use in patients with status epilepticus","volume":"3","author":"S H Mahmoud","year":"2018","journal-title":"Epilepsia Open"},{"issue":"01","key":"ref48","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s12028-019-00738-z","article-title":"Perampanel for refractory status epilepticus\u2026 another tool in the armamentarium","volume":"31","author":"S Hocker","year":"2019","journal-title":"Neurocrit Care"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.yebeh.2015.01.036","article-title":"Efficacy of perampanel in refractory nonconvulsive status epilepticus and simple partial status epilepticus","volume":"45","author":"J Redecker","year":"2015","journal-title":"Epilepsy Behav"},{"issue":"S 02","key":"ref50","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/epi.14494","article-title":"Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit: a single-center audit of 30 patients","volume":"59","author":"A Rohracher","year":"2018","journal-title":"Epilepsia"},{"issue":"04","key":"ref51","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00134-016-4501-6","article-title":"What's new in refractory status epilepticus?","volume":"43","author":"S Legriel","year":"2017","journal-title":"Intensive Care Med"},{"issue":"03","key":"ref52","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s12028-018-0560-6","article-title":"Safety and efficiency of intravenous push lacosamide administration","volume":"29","author":"K E Davidson","year":"2018","journal-title":"Neurocrit Care"},{"issue":"01","key":"ref53","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s12028-019-00708-5","article-title":"Safety and tolerability of rapid administration undiluted levetiracetam","volume":"32","author":"O Morgan","year":"2019","journal-title":"Neurocrit Care"},{"issue":"08","key":"ref55","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2165\/11590250-000000000-00000","article-title":"Pharmacokinetics of diazepam administered intramuscularly by autoinjector versus rectal gel in healthy subjects: a phase I, randomized, open-label, single-dose, crossover, single-centre study","volume":"31","author":"M J Lamson","year":"2011","journal-title":"Clin Drug Investig"},{"issue":"11","key":"ref56","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/00912700122012779","article-title":"Bioavailability and pharmacokinetics of lorazepam after intranasal, intravenous, and intramuscular administration","volume":"41","author":"D P Wermeling","year":"2001","journal-title":"J Clin Pharmacol"},{"issue":"04","key":"ref58","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/j.1875-9114.1996.tb03646.x","article-title":"The safety, tolerability, and pharmacokinetics of fosphenytoin after intramuscular and intravenous administration in neurosurgery patients","volume":"16","author":"B A Boucher","year":"1996","journal-title":"Pharmacotherapy"},{"issue":"03","key":"ref59","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0920-1211(97)00054-5","article-title":"Intramuscular fosphenytoin (Cerebyx) in patients requiring a loading dose of phenytoin","volume":"28","author":"R E Ramsay","year":"1997","journal-title":"Epilepsy Res"},{"issue":"06","key":"ref60","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1053\/seiz.2000.0425","article-title":"Is intranasal midazolam an effective rescue medication in adolescents and adults with severe epilepsy?","volume":"9","author":"M Scheepers","year":"2000","journal-title":"Seizure"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.lfs.2017.12.025","article-title":"Mechanism of intranasal drug delivery directly to the brain","volume":"195","author":"T P Crowe","year":"2018","journal-title":"Life Sci"},{"issue":"03","key":"ref62","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1023\/B:PHAR.0000026823.82950.ff","article-title":"Nasal route and drug delivery systems","volume":"26","author":"S T\u00fcrker","year":"2004","journal-title":"Pharm World Sci"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.eplepsyres.2008.10.005","article-title":"A pharmacokinetic and pharmacodynamic study, in healthy volunteers, of a rapidly absorbed intranasal midazolam formulation","volume":"83","author":"D P Wermeling","year":"2009","journal-title":"Epilepsy Res"},{"issue":"02","key":"ref64","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.yebeh.2004.01.003","article-title":"Comparison of intranasal midazolam with intravenous diazepam for treating acute seizures in children","volume":"5","author":"T Mahmoudian","year":"2004","journal-title":"Epilepsy Behav"},{"issue":"04","key":"ref65","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/bcp.13163","article-title":"Pharmacokinetics and pharmacodynamics of a new highly concentrated intranasal midazolam formulation for conscious sedation","volume":"83","author":"L Schrier","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/978-1-4939-3816-2_6","article-title":"Methods of drug delivery in neurotrauma","volume":"1462","author":"Y Deng-Bryant","year":"2016","journal-title":"Methods Mol Biol"},{"issue":"04","key":"ref67","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00003088-198207040-00002","article-title":"Rectal drug administration: clinical pharmacokinetic considerations","volume":"7","author":"A G de Boer","year":"1982","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"ref68","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.addr.2012.01.017","article-title":"Current oral and non-oral routes of antiepileptic drug delivery","volume":"64","author":"G D Anderson","year":"2012","journal-title":"Adv Drug Deliv Rev"},{"issue":"02","key":"ref69","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0378-5173(79)90057-7","article-title":"Biopharmaceutics of rectal administration of drugs in man 7. Absorption rate and bioavailability of phenobarbital and its sodium salt from rectal dosage forms","volume":"4","author":"F Moolenaar","year":"1979","journal-title":"Int J Pharm"},{"issue":"26","key":"ref70","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1056\/NEJM199806253382602","article-title":"A comparison of rectal diazepam gel and placebo for acute repetitive seizures","volume":"338","author":"F E Dreifuss","year":"1998","journal-title":"N Engl J Med"},{"issue":"03","key":"ref71","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1528-1157.1998.tb01375.x","article-title":"Buccal absorption of midazolam: pharmacokinetics and EEG pharmacodynamics","volume":"39","author":"R C Scott","year":"1998","journal-title":"Epilepsia"},{"issue":"01","key":"ref72","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1542\/peds.2007-0930","article-title":"Comparison of buccal midazolam with rectal diazepam in the treatment of prolonged seizures in Ugandan children: a randomized clinical trial","volume":"121","author":"A Mpimbaza","year":"2008","journal-title":"Pediatrics"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0140-6736(98)06425-3","article-title":"Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial","volume":"353","author":"R C Scott","year":"1999","journal-title":"Lancet"},{"issue":"02","key":"ref74","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s40272-013-0009-5","article-title":"The cost effectiveness of licensed oromucosal midazolam (Buccolam(\u00ae)) for the treatment of children experiencing acute epileptic seizures: an approach when trial evidence is limited","volume":"15","author":"D Lee","year":"2013","journal-title":"Paediatr Drugs"},{"issue":"S 01","key":"ref75","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1757-7241-18-S1-P26","article-title":"Preferred anatomic site for intraosseous infusion in Danish emergency departments","volume":"18","author":"R Molin","year":"2010","journal-title":"Scand J Trauma Resusc Emerg Med"},{"issue":"03","key":"ref76","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/TA.0b013e3181b16f42","article-title":"Proximal humerus intraosseous infusion: a preferred emergency venous access","volume":"67","author":"J H Paxton","year":"2009","journal-title":"J Trauma"},{"issue":"04","key":"ref77","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1097\/ALN.0000000000000140","article-title":"Vascular access in resuscitation: is there a role for the intraosseous route?","volume":"120","author":"J A Anson","year":"2014","journal-title":"Anesthesiology"},{"issue":"10","key":"ref78","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1592\/phco.27.10.1425","article-title":"Anticonvulsant hypersensitivity syndrome: implications for pharmaceutical care","volume":"27","author":"K H Bohan","year":"2007","journal-title":"Pharmacotherapy"},{"issue":"05","key":"ref79","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1186\/cc3742","article-title":"Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence?","volume":"9","author":"P ER Lheureux","year":"2005","journal-title":"Crit Care"},{"issue":"01","key":"ref80","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2146\/ajhp110049","article-title":"Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy","volume":"69","author":"C M Mock","year":"2012","journal-title":"Am J Health Syst Pharm"},{"issue":"01","key":"ref81","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1528-1167.2012.03671.x","article-title":"Enzyme induction with antiepileptic drugs: cause for concern?","volume":"54","author":"M J Brodie","year":"2013","journal-title":"Epilepsia"},{"issue":"12","key":"ref82","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1345\/aph.1M296","article-title":"The effect of carbapenem antibiotics on plasma concentrations of valproic acid","volume":"43","author":"E E Mancl","year":"2009","journal-title":"Ann Pharmacother"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ebcr.2014.09.001","article-title":"Topiramate-induced hyperammonemic encephalopathy in a patient with mental retardation: a case report and review of the literature","volume":"4","author":"S Tantikittichaikul","year":"2015","journal-title":"Epilepsy Behav Case Rep"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1345\/aph.19355","article-title":"Phenytoin and enteral feedings: does evidence support an interaction?","volume":"34","author":"S C Au Yeung","year":"2000","journal-title":"Ann Pharmacother"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.seizure.2015.09.007","article-title":"Concomitant lamotrigine use is associated with decreased efficacy of the ketogenic diet in childhood refractory epilepsy","volume":"32","author":"E JTM van der Louw","year":"2015","journal-title":"Seizure"},{"issue":"05","key":"ref86","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","article-title":"Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update","volume":"40","author":"P N Patsalos","year":"2018","journal-title":"Ther Drug Monit"},{"key":"ref87","first-page":"183","article-title":"Correlation between measured and calculated free phenytoin serum concentration in neurointensive care patients with hypoalbuminemia","volume":"10","author":"S-S Javadi","year":"2018","journal-title":"Clin Pharmacol"},{"issue":"09","key":"ref88","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamadermatol.2013.4114","article-title":"Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"149","author":"W Tangamornsuksan","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"02","key":"ref89","first-page":"107","article-title":"HLA-B*1502 increases the risk of phenytoin or lamotrigine induced Stevens-Johnson Syndrome\/toxic epidermal necrolysis: evidence from a meta-analysis of nine case-control studies","volume":"65","author":"X Li","year":"2015","journal-title":"Drug Res (Stuttg)"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.seizure.2018.06.024","article-title":"Association between HLA alleles and lamotrigine-induced cutaneous adverse drug reactions in Asian populations: a meta-analysis","volume":"60","author":"Y Deng","year":"2018","journal-title":"Seizure"},{"issue":"06","key":"ref91","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/MOP.0000000000000154","article-title":"Pediatric status epilepticus management","volume":"26","author":"N S Abend","year":"2014","journal-title":"Curr Opin Pediatr"},{"issue":"04","key":"ref92","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.bja.2018.12.025","article-title":"Propofol infusion syndrome: a structured literature review and analysis of published case reports","volume":"122","author":"S Hemphill","year":"2019","journal-title":"Br J Anaesth"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.yebeh.2017.07.002","article-title":"Status epilepticus in pregnancy: etiology, management, and clinical outcomes","volume":"76","author":"K R Rajiv","year":"2017","journal-title":"Epilepsy Behav"},{"issue":"03","key":"ref94","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/epi.12109","article-title":"Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications","volume":"54","author":"T Tomson","year":"2013","journal-title":"Epilepsia"},{"issue":"10","key":"ref95","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1517\/14740338.2015.1085503","article-title":"Safety of anticonvulsant agents in pregnancy","volume":"14","author":"H N Moussa","year":"2015","journal-title":"Expert Opin Drug Saf"},{"issue":"S 02","key":"ref96","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/epi.14497","article-title":"Status epilepticus in the elderly","volume":"59","author":"I E Leppik","year":"2018","journal-title":"Epilepsia"},{"issue":"11","key":"ref97","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11910-016-0696-8","article-title":"Treatment of epilepsy in the elderly","volume":"16","author":"P V Motika","year":"2016","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"07","key":"ref98","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/epi.16068","article-title":"The medical treatment of epilepsy in the elderly: a systematic review and meta-analysis","volume":"60","author":"N Lezaic","year":"2019","journal-title":"Epilepsia"},{"issue":"05","key":"ref99","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1378\/chest.11-1396","article-title":"Introduction to drug pharmacokinetics in the critically ill patient","volume":"141","author":"B S Smith","year":"2012","journal-title":"Chest"},{"key":"ref100","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jcrc.2016.06.023","article-title":"Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy","volume":"36","author":"K S Smetana","year":"2016","journal-title":"J Crit Care"},{"issue":"03","key":"ref101","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s12028-015-0127-8","article-title":"Augmented renal clearance in patients with subarachnoid hemorrhage","volume":"23","author":"C C May","year":"2015","journal-title":"Neurocrit Care"},{"issue":"01","key":"ref102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/11318140-000000000-00000","article-title":"Augmented renal clearance: implications for antibacterial dosing in the critically ill","volume":"49","author":"A A Udy","year":"2010","journal-title":"Clin Pharmacokinet"},{"issue":"03","key":"ref103","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/phar.2231","article-title":"Augmented renal clearance","volume":"39","author":"A M Cook","year":"2019","journal-title":"Pharmacotherapy"},{"issue":"10","key":"ref104","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1097\/CCM.0000000000001223","article-title":"Pharmacokinetic and other considerations for drug therapy during targeted temperature management","volume":"43","author":"K M \u0160unji\u0107","year":"2015","journal-title":"Crit Care Med"},{"issue":"04","key":"ref105","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/epi.14016","article-title":"Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions","volume":"59","author":"L J Hirsch","year":"2018","journal-title":"Epilepsia"},{"issue":"18","key":"ref106","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1212\/WNL.0000000000001940","article-title":"New-onset refractory status epilepticus: etiology, clinical features, and outcome","volume":"85","author":"N Gaspard","year":"2015","journal-title":"Neurology"},{"key":"ref107","first-page":"227","article-title":"Autoimmune epilepsy","volume":"22","author":"N Gaspard","year":"2016","journal-title":"Continuum (Minneap Minn)"},{"issue":"10","key":"ref108","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11910-015-0589-2","article-title":"Treatment of super-refractory status epilepticus","volume":"15","author":"A Bayrlee","year":"2015","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"08","key":"ref109","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJM199008233230801","article-title":"A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures","volume":"323","author":"N R Temkin","year":"1990","journal-title":"N Engl J Med"},{"issue":"04","key":"ref110","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3171\/jns.1999.91.4.0593","article-title":"Valproate therapy for prevention of posttraumatic seizures: a randomized trial","volume":"91","author":"N R Temkin","year":"1999","journal-title":"J Neurosurg"},{"issue":"01","key":"ref111","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1227\/NEU.0000000000001432","article-title":"Guidelines for the management of severe traumatic brain injury, fourth edition","volume":"80","author":"N Carney","year":"2017","journal-title":"Neurosurgery"},{"key":"ref112","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.wneu.2018.11.076","article-title":"The effectiveness of antiepileptic medications as prophylaxis of early seizure in patients with traumatic brain injury compared with placebo or no treatment: a systematic review and meta-analysis","volume":"122","author":"R Wat","year":"2019","journal-title":"World Neurosurg"},{"issue":"03","key":"ref113","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/TA.0b013e3182826e84","article-title":"A prospective multicenter comparison of levetiracetam versus phenytoin for early posttraumatic seizure prophylaxis","volume":"74","author":"K Inaba","year":"2013","journal-title":"J Trauma Acute Care Surg"},{"issue":"01","key":"ref114","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1227\/01.NEU.0000249207.66225.D9","article-title":"Three-day phenytoin prophylaxis is adequate after subarachnoid hemorrhage","volume":"60","author":"S Chumnanvej","year":"2007","journal-title":"Neurosurgery"},{"issue":"02","key":"ref115","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s12028-017-0440-5","article-title":"A randomized trial of brief versus extended seizure prophylaxis after aneurysmal subarachnoid hemorrhage","volume":"28","author":"T Human","year":"2018","journal-title":"Neurocrit Care"},{"issue":"02","key":"ref116","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3171\/JNS-07\/08\/0253","article-title":"Outcome in patients with subarachnoid hemorrhage treated with antiepileptic drugs","volume":"107","author":"A J Rosengart","year":"2007","journal-title":"J Neurosurg"},{"issue":"03","key":"ref117","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/01.STR.0000141936.36596.1e","article-title":"Phenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhage","volume":"36","author":"A M Naidech","year":"2005","journal-title":"Stroke"},{"issue":"03","key":"ref118","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-2125.1991.tb03908.x","article-title":"Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients","volume":"32","author":"A Tartara","year":"1991","journal-title":"Br J Clin Pharmacol"},{"issue":"06","key":"ref119","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1161\/STR.0b013e3182587839","article-title":"Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association\/american Stroke Association","volume":"43","author":"E S Connolly Jr","year":"2012","journal-title":"Stroke"},{"issue":"02","key":"ref120","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s12028-011-9605-9","article-title":"Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society's Multidisciplinary Consensus Conference","volume":"15","author":"M N Diringer","year":"2011","journal-title":"Neurocrit Care"},{"issue":"07","key":"ref121","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1161\/STR.0000000000000069","article-title":"Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"46","author":"J C Hemphill III","year":"2015","journal-title":"Stroke"},{"issue":"02","key":"ref122","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s12028-017-0385-8","article-title":"Prophylactic anticonvulsants in intracerebral hemorrhage","volume":"27","author":"J Mackey","year":"2017","journal-title":"Neurocrit Care"},{"issue":"12","key":"ref123","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1161\/STROKEAHA.109.559948","article-title":"Anticonvulsant use and outcomes after intracerebral hemorrhage","volume":"40","author":"A M Naidech","year":"2009","journal-title":"Stroke"},{"issue":"01","key":"ref124","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s12028-009-9207-y","article-title":"Prophylactic antiepileptic drug use is associated with poor outcome following ICH","volume":"11","author":"S R Mess\u00e9","year":"2009","journal-title":"Neurocrit Care"},{"issue":"21","key":"ref125","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1161\/01.CIR.103.21.2644","article-title":"Recommendations for the management of intracranial arteriovenous malformations: a statement for healthcare professionals from a special writing group of the Stroke Council, American Stroke Association","volume":"103","author":"C S Ogilvy","year":"2001","journal-title":"Circulation"},{"issue":"02","key":"ref126","first-page":"CD007286","article-title":"Antiepileptic drugs as prophylaxis for post-craniotomy seizures","author":"J Pulman","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"03","key":"ref127","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1161\/STR.0000000000000158","article-title":"2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"49","author":"W J Powers","year":"2018","journal-title":"Stroke"},{"issue":"03","key":"ref128","doi-asserted-by":"crossref","first-page":"E195","DOI":"10.1093\/neuros\/nyy545","article-title":"Congress of Neurological Surgeons systematic review and evidence-based guidelines on the role of prophylactic anticonvulsants in the treatment of adults with metastatic brain tumors","volume":"84","author":"C C Chen","year":"2019","journal-title":"Neurosurgery"},{"issue":"01","key":"ref129","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11060-009-0056-5","article-title":"The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline","volume":"96","author":"T Mikkelsen","year":"2010","journal-title":"J Neurooncol"},{"issue":"03","key":"ref130","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3171\/2011.4.JNS101585","article-title":"Prophylactic antiepileptic drug therapy in patients undergoing supratentorial meningioma resection: a systematic analysis of efficacy","volume":"115","author":"R J Komotar","year":"2011","journal-title":"J Neurosurg"},{"issue":"02","key":"ref131","first-page":"CD004424","article-title":"Antiepileptic drugs for preventing seizures in people with brain tumors","author":"I W Tremont-Lukats","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"05","key":"ref132","first-page":"CD010247","article-title":"Antiepileptic drugs for the primary and secondary prevention of seizures in viral encephalitis","author":"S Pandey","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"year":"2012","author":"R N Lipari","key":"ref133"},{"issue":"04","key":"ref134","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/BF02190260","article-title":"Development of a rating scale for quantitative measurement of the alcohol withdrawal syndrome","volume":"241","author":"M Banger","year":"1992","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"06","key":"ref135","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/oxfordjournals.alcalc.a008326","article-title":"A new rating scale for the assessment of the alcohol-withdrawal syndrome (AWS scale)","volume":"32","author":"T Wetterling","year":"1997","journal-title":"Alcohol Alcohol"},{"issue":"11","key":"ref136","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/j.1360-0443.1989.tb00737.x","article-title":"Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar)","volume":"84","author":"J T Sullivan","year":"1989","journal-title":"Br J Addict"},{"issue":"08","key":"ref137","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/jhm.928","article-title":"Treating alcohol withdrawal with oral baclofen: a randomized, double-blind, placebo-controlled trial","volume":"6","author":"J E Lyon","year":"2011","journal-title":"J Hosp Med"},{"issue":"05","key":"ref138","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1097\/CCM.0000000000000141","article-title":"A randomized, double-blind, placebo-controlled dose range study of dexmedetomidine as adjunctive therapy for alcohol withdrawal","volume":"42","author":"S W Mueller","year":"2014","journal-title":"Crit Care Med"},{"issue":"01","key":"ref139","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/1060028014555859","article-title":"Evaluation of adjunctive ketamine to benzodiazepines for management of alcohol withdrawal syndrome","volume":"49","author":"A Wong","year":"2015","journal-title":"Ann Pharmacother"},{"issue":"04","key":"ref140","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ajem.2009.10.010","article-title":"A prospective, randomized, trial of phenobarbital versus benzodiazepines for acute alcohol withdrawal","volume":"29","author":"G W Hendey","year":"2011","journal-title":"Am J Emerg Med"},{"issue":"03","key":"ref141","doi-asserted-by":"crossref","first-page":"592.e2","DOI":"10.1016\/j.jemermed.2012.07.056","article-title":"Phenobarbital for acute alcohol withdrawal: a prospective randomized double-blind placebo-controlled study","volume":"44","author":"J Rosenson","year":"2013","journal-title":"J Emerg Med"},{"key":"ref142","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jocn.2016.02.028","article-title":"Comparison of enteral ethanol and benzodiazepines for alcohol withdrawal in neurocritical care patients","volume":"31","author":"G Gipson","year":"2016","journal-title":"J Clin Neurosci"},{"issue":"06","key":"ref143","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1053\/apmr.2002.32820","article-title":"Abrupt withdrawal from intrathecal baclofen: recognition and management of a potentially life-threatening syndrome","volume":"83","author":"R J Coffey","year":"2002","journal-title":"Arch Phys Med Rehabil"},{"issue":"06","key":"ref144","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3171\/jns.2005.102.6.1133","article-title":"Prolonged intrathecal baclofen withdrawal syndrome. Case report and discussion of current therapeutic management","volume":"102","author":"A F Douglas","year":"2005","journal-title":"J Neurosurg"},{"issue":"10","key":"ref145","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/PEC.0b013e318188a952","article-title":"Intrathecal baclofen withdrawal resembling serotonin syndrome in an adolescent boy with cerebral palsy","volume":"24","author":"M L Salazar","year":"2008","journal-title":"Pediatr Emerg Care"},{"issue":"03","key":"ref146","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/00000542-200509000-00033","article-title":"Low-dose propofol infusion for controlling acute hyperspasticity after withdrawal of intrathecal baclofen therapy","volume":"103","author":"G L Ackland","year":"2005","journal-title":"Anesthesiology"},{"issue":"12","key":"ref147","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1097\/PHM.0b013e31815b5c58","article-title":"Cyproheptadine for pediatric intrathecal baclofen withdrawal: a case report","volume":"86","author":"J A Saveika","year":"2007","journal-title":"Am J Phys Med Rehabil"},{"issue":"03","key":"ref148","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0003-9993(98)90021-1","article-title":"Hyperthermia, rhabdomyolysis, and disseminated intravascular coagulation associated with baclofen pump catheter failure","volume":"79","author":"R K Reeves","year":"1998","journal-title":"Arch Phys Med Rehabil"},{"issue":"06","key":"ref149","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/AAP.0b013e3181b4cc6b","article-title":"Prevention of intrathecal baclofen withdrawal syndrome: successful use of a temporary intrathecal catheter","volume":"34","author":"A Bellinger","year":"2009","journal-title":"Reg Anesth Pain Med"},{"issue":"03","key":"ref151","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s12028-013-9935-x","article-title":"The epidemiology of status epilepticus in the United States","volume":"20","author":"B S Dham","year":"2014","journal-title":"Neurocrit Care"},{"issue":"15","key":"ref152","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1212\/WNL.0000000000002023","article-title":"Seizures as adverse events of antibiotic drugs: A systematic review","volume":"85","author":"R Sutter","year":"2015","journal-title":"Neurology"},{"issue":"10","key":"ref153","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1001\/archneurol.2011.204","article-title":"Continuous epileptiform discharges in patients treated with cefepime or meropenem","volume":"68","author":"G Naeije","year":"2011","journal-title":"Arch Neurol"},{"issue":"01","key":"ref154","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s13054-017-1856-1","article-title":"Cefepime-induced neurotoxicity: a systematic review","volume":"21","author":"L E Payne","year":"2017","journal-title":"Crit Care"},{"issue":"08","key":"ref155","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1093\/jac\/dku111","article-title":"The risk of seizures among the carbapenems: a meta-analysis","volume":"69","author":"J P Cannon","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"14","key":"ref156","doi-asserted-by":"crossref","first-page":"e3173","DOI":"10.1097\/MD.0000000000003173","article-title":"Calcineurin inhibitors associated posterior reversible encephalopathy syndrome in solid organ transplantation: report of 2 cases and literature review","volume":"95","author":"T Song","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"02","key":"ref157","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2165\/00002018-200225020-00004","article-title":"Effects of psychotropic drugs on seizure threshold","volume":"25","author":"F Pisani","year":"2002","journal-title":"Drug Saf"},{"issue":"11","key":"ref158","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1111\/add.14708","article-title":"Psychostimulant use and the brain","volume":"114","author":"J M Lappin","year":"2019","journal-title":"Addiction"},{"issue":"03","key":"ref160","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/QCO.0000000000000546","article-title":"Immune-mediated encephalitis for the infectious disease specialist","volume":"32","author":"A Venkatesan","year":"2019","journal-title":"Curr Opin Infect Dis"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.seizure.2018.09.018","article-title":"New onset refractory status epilepticus (NORSE)","volume":"68","author":"C Sculier","year":"2019","journal-title":"Seizure"},{"issue":"04","key":"ref162","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s13311-016-0442-6","article-title":"Tocilizumab in autoimmune encephalitis refractory to rituximab: an institutional cohort study","volume":"13","author":"W-J Lee","year":"2016","journal-title":"Neurotherapeutics"},{"key":"ref163","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nrneurol.2012.222","article-title":"Epilepsy: perampanel-new promise for refractory epilepsy?","volume":"8","author":"W Loscher","year":"2012","journal-title":"Nat Rev Neurol"}],"container-title":["Seminars in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0040-1718721.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T08:07:03Z","timestamp":1723882023000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0040-1718721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,11]]},"references-count":159,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2020,11,24]]},"published-print":{"date-parts":[[2020,12]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0040-1718721","relation":{},"ISSN":["0271-8235","1098-9021"],"issn-type":[{"type":"print","value":"0271-8235"},{"type":"electronic","value":"1098-9021"}],"subject":[],"published":{"date-parts":[[2020,11,11]]}}}